Skip to content

COVID-19 Serum Proteomics Translation Guidelines for Diagnosis and Treatment of Novel Coronavirus Infection and Related Diseases

COVID-19 Serum Proteomics Translation Guidelines for Diagnosis and Treatment of Novel Coronavirus Infection and Related Diseases

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400080045
Enrollment
Unknown
Registered
2024-01-18
Start date
2023-08-01
Completion date
Unknown
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

Patients with acute exacerbation requiring hospitalization during the long-term COVID-19 pandemic:None

Sponsors

Shandong Provincial Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: (1) Age = 18 years. (2) The patient complained of a previous positive nucleic acid test or antigenic self-assay for novel coronavirus. (3) The patient previously been hospitalized for COVID-19 and now requires hospitalization again due to acute exacerbation of COVID-19. (4) Patients primarily diagnosed and treated at our hospital. (5) Complete clinical information records. (6) Must sign an informed consent form before inclusion in the cohort and be able to participate in the study protocol and follow-up according to the protocol.

Exclusion criteria

Exclusion criteria: (1) Women of childbearing age who are currently pregnant or breastfeeding. (2) Abnormal mental state. (3) History of drug abuse and drug use (4) Participants in other clinical studies prior to enrolment.

Design outcomes

Primary

MeasureTime frame
Acute-phase response proteins;Lipid metabolism-related indicators;Virus replication-related proteins;Pulmonary fibrosis-related proteins;

Secondary

MeasureTime frame
Classification and counting of immune-related cells;

Countries

China

Contacts

Public ContactLiu Yi

Shandong Provincial Hospital Affiliated to Shandong First Medical University

yiliu-sdu@163.com+86 151 6888 8626

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026